Cytogenetic and Molecular Monitoring of Residual Disease in Chronic Myeloid Leukaemia

2002 ◽  
pp. 32-43
Author(s):  
J. Kaeda ◽  
A. Chase ◽  
J.M. Goldman
Keyword(s):  
Chronic Myeloid Leukaemia ◽  
Myeloid Leukaemia ◽  
Residual Disease ◽  
Molecular Monitoring

Cytogenetic and Molecular Monitoring of Residual Disease in Chronic Myeloid Leukaemia

2002 ◽  
Vol 107 (2) ◽  
pp. 64-75 ◽  
Author(s):  
Jaspal Kaeda ◽  
Andrew Chase ◽  
John M. Goldman
Keyword(s):  
Chronic Myeloid Leukaemia ◽  
Myeloid Leukaemia ◽  
Residual Disease ◽  
Molecular Monitoring

Cepheid xpert monitor platform for the confirmation of BCR-ABL1 IS conversion factors for the molecular monitoring of chronic myeloid leukaemia

2016 ◽  
Vol 49 ◽  
pp. 47-50 ◽  
Author(s):  
Gareth Gerrard ◽  
Hui En Foong ◽  
Katherine Mudge ◽  
Mary Alikian ◽  
Jane F. Apperley ◽  
...  
Keyword(s):  
Chronic Myeloid Leukaemia ◽  
Myeloid Leukaemia ◽  
Molecular Monitoring ◽  
Conversion Factors

scholarly journals Present and future of molecular monitoring in chronic myeloid leukaemia

2016 ◽  
Vol 173 (3) ◽  
pp. 337-349 ◽  
Author(s):  
Simona Soverini ◽  
Caterina De Benedittis ◽  
Manuela Mancini ◽  
Giovanni Martinelli
Keyword(s):  
Chronic Myeloid Leukaemia ◽  
Myeloid Leukaemia ◽  
Molecular Monitoring

BCR-ABL1 expression, RT-qPCR and treatment decisions in chronic myeloid leukaemia

2016 ◽  
Vol 69 (9) ◽  
pp. 817-821 ◽  
Author(s):  
Susan Latham ◽  
Paul A Bartley ◽  
Bradley Budgen ◽  
David M Ross ◽  
Elizabeth Hughes ◽  
...  
Keyword(s):  
Chronic Myeloid Leukaemia ◽  
Myeloid Leukaemia ◽  
Treatment Guidelines ◽  
Residual Disease ◽  
Limit Of Detection ◽  
Cell Number ◽  
Expression Level ◽  
Response To Treatment ◽  
Leukaemic Cells ◽  
The Difference

AimsRT-qPCR is used to quantify minimal residual disease (MRD) in chronic myeloid leukaemia (CML) in order to make decisions on treatment, but its results depend on the level of BCR-ABL1 expression as well as leukaemic cell number. The aims of the study were to quantify inter-individual differences in expression level, to determine the relationship between expression level and response to treatment, and to investigate the effect of expression level on interpretation of the RT-qPCR result.MethodsBCR-ABL1 expression was studied in 248 samples from 65 patients with CML by determining the difference between MRD quantified by RT-qPCR and DNA-qPCR. The results were analysed statistically and by simple indicative modelling.ResultsInter-individual levels of expression approximated a normal distribution with an SD of 0.36 log. Expression at diagnosis correlated with expression during treatment. Response to treatment, as measured by the number of leukaemic cells after 3, 6 or 12 months of treatment, was not related to the level of expression. Indicative modelling suggested that interpretation of RT-qPCR results in relation to treatment guidelines could be affected by variation in expression when MRD was around 10% at 3 months and by both expression variation and Poisson variation when MRD was around or below the limit of detection of RT-qPCR.ConclusionsVariation between individuals in expression of BCR-ABL1 can materially affect interpretation of the RT-qPCR when this test is used to make decisions on treatment.

Sign in / Sign up

Export Citation Format

Share Document